Drug Trial Radar · NCT03846310
A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer
Last checked: Nov 19, 2026Latest source record: Dec 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
77
Actual
Start
Apr 1, 2019
Primary completion
Nov 18, 2024
Study completion Nov 18, 2024
Sponsor
- Lead sponsor
- Arcus Biosciences, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Gilead Sciences
- First posted
- Feb 19, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/1b, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and clinical activity of etrumadenant (AB928) in combination with carboplatin and pemetrexed, with or without an anti-PD-1 antibody (pembrolizumab or zimberelimab), in participants with non-squamous Non-Small Cell Lung Cancer (NSCLC).
Conditions
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Nonsquamous Nonsmall Cell Neoplasm of Lung
- Sensitizing EGFR Gene Mutation
Interventions
EtrumadenantDrug
Etrumadenant is an A2aR and A2bR antagonist
ZimberelimabDrug
Zimberelimab is a fully human anti-PD-1 monoclonal antibody
CarboplatinDrug
Carboplatin administered as part of standard chemotherapy regimen
PemetrexedDrug
Pemetrexed administered as part of standard chemotherapy regimen
PembrolizumabDrug
Pembrolizumab is a humanized anti-PD-1 monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with Adverse EventsTime frame: From first study treatment administration until up to 90 days after the last dose (Approximately 1 year)
- Percentage of participants who experience a Dose Limiting ToxicityTime frame: From first study treatment administration through Day 21
Locations
22 sites in 4 countries. Site status is shown where the registry gives one.
Arizona Cancer Research Center (ACRC)
Tucson, Arizona
SCRI Florida Cancer Specialists - South
Fort Myers, Florida
SCRI Florida Cancer Specialists - North
Tavares, Florida
SCRI Tennessee Oncology - Nashville
Nashville, Tennessee
USO Texas Oncology - Dallas (Baylor Charles A. Sammons Cancer Center)
Dallas, Texas
USO Virginia Cancer Specialist
Fairfax, Virginia
USO Virginia Oncology Associates
Norfolk, Virginia
Medical Oncology Associates/Summit Cancer Center
Spokane, Washington
National University Hospital
Singapore, Singapore
National Cancer Centre Singapore
Singapore, Singapore
Chungbuk National University Hospital
Cheongju-si, South Korea
Bundang CHA Medical Center
Seongnam-si, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Asan Medical Centre
Seoul, South Korea
Seoul St. Mary's Hospital
Seoul, South Korea
Seoul National University Hospital
Suwon, South Korea
The Catholic University of Korea St. Vincent Hospital
Suwon, Gyeonggi-do, South Korea
Changhua Christian Hospital
Changhua, Taiwan
Taipei Medical University - Shuang Ho Hospital
New Taipei City, Taiwan
Chi Mei Hospital, Liouying
Tainan, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Tri Service General Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.